Syntimmune, Inc., a New York-based development-stage company advancing novel treatments for IgG-mediated autoimmune diseases based on expertise in FcRn biology, raised a second $10m tranche of its $26m Series A financing.
The round is co-led by Apple Tree Partners and Baxalta Ventures, the corporate venture capital arm of Baxalta Incorporated, with participation from Partners Innovation Fund and additional investors.
The company will use the funds to complete the anticipated Phase 1a clinical trial in healthy volunteers of Syntimmune’s lead candidate, SYNT001.
Syntimmune intends to submit an IND application to the Food and Drug Administration for SYNT001 in mid-2016 to authorize initiation of the Phase 1a study later this year.
Founded in 2013 by Laurence Blumberg, M.D., COO, Syntimmune is advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn), a validated target for IgG-mediated autoimmune diseases. It represents a central common pathway that enables abnormal IgG responses.
Syntimmune’s lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases.
Since its founding, the company has received a total of $28m in funding.